Pennington Biomedical Research Center

1. VIVUS, Inc. $116,925 3 payments
2. Moderna TX, Inc. $106,118 36 payments
3. Pfizer Inc. $20,824 5 payments
4. Novartis Pharmaceuticals Corporation $16,268 1 payment
5. Biohaven Pharmaceuticals, Inc. $5,480 1 payment
6. Dexcom, Inc. $556 1 payment

1. A Study of VI-0521 on Ambulatory Blood Pressure in Overweight or Obese Subject $116,925 3 payments
2. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $73,020 28 payments
3. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. $33,098 8 payments
4. A Phase 2A Randomized Doubleblind Sponsoropen Placebocontrolled Parallel Group Doseranging Study of Pf07976016 to Assess Safety and Efficacy in Adult Participants With Obesity $17,707 2 payments
5. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $16,268 1 payment
6. A Seamless Phase 2A-B Randomized Double-blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimers Disease $5,480 1 payment
7. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $2,104 1 payment
8. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy Safety and Tolerability of Ponsegromab in Patients With Cancer Cachexia and Elevated Concentrations of Gdf15 Followed By An Optional Openlabel Treatment Period $1,013 2 payments
9. Development of A Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study ???Cgm-Peptide??? $556 1 payment

1. Other $116,925 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.